A recent study demonstrated antifungal activity of dark chemical matter (DCM) compounds that were otherwise inactive in more than 100 HTS assays. These compounds were proposed to possess unique activity and ‘clean’ safety profiles. Here, we present an outlook of the promiscuity and safety of these compounds by retrospectively comparing their chemical and biological spaces with those of drugs. Significant amounts of marketed drugs (16%), withdrawn drugs (16.5%) and natural compounds (3.5%) share structural identity with DCM. Compound promiscuity assessment indicates that dark matter compounds could potentially interact with multiple biological targets. Further, thousands of DCM compounds showed presence of frequent-hitting pan-assay interference compound (PAINS) substructures. In light of these observations, filtering these compounds from screening libraries can be an irrevocable loss.

最近的一项研究表明，暗化学物质（DCM）化合物的抗真菌活性在100多种HTS分析中没有活性。提出这些化合物具有独特的活性和“清洁”的安全性。在这里，通过回顾性比较它们与药物的化学和生物空间，我们对这些化合物的滥交和安全性提出了展望。大量市售药物（16％），已撤回药物（16.5％）和天然化合物（3.5％）与DCM具有结构同一性。化合物滥交评估表明，暗物质可能与多种生物靶标发生相互作用。此外，成千上万的DCM化合物显示出频繁击中的泛测定干扰化合物（PAINS）子结构。根据这些观察，